Arvinas (ARVN) and Pfizer (PFE) announced that the U.S. FDA has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor positive/human growth epidermal growth factor 2 negative locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Vepdegestrant is a novel oral PROteolysis Targeting Chimera ER degrader that is being jointly developed by Arvinas and Pfizer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARVN:
- 3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts
- Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Arvinas initiated with a Buy at Goldman Sachs
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call